Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 27.60
ENZ's Cash to Debt is ranked higher than
67% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. ENZ: 27.60 )
Ranked among companies with meaningful Cash to Debt only.
ENZ' s Cash to Debt Range Over the Past 10 Years
Min: 2.06  Med: No Debt Max: No Debt
Current: 27.6
Equity to Asset 0.80
ENZ's Equity to Asset is ranked higher than
80% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. ENZ: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
ENZ' s Equity to Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.91 Max: 0.96
Current: 0.8
0.57
0.96
Interest Coverage 345.61
ENZ's Interest Coverage is ranked higher than
59% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. ENZ: 345.61 )
Ranked among companies with meaningful Interest Coverage only.
ENZ' s Interest Coverage Range Over the Past 10 Years
Min: 345.61  Med: No Debt Max: No Debt
Current: 345.61
F-Score: 6
Z-Score: 8.38
M-Score: -2.62
WACC vs ROIC
13.83%
192.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 45.73
ENZ's Operating margin (%) is ranked higher than
98% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. ENZ: 45.73 )
Ranked among companies with meaningful Operating margin (%) only.
ENZ' s Operating margin (%) Range Over the Past 10 Years
Min: -39.63  Med: -19.63 Max: 45.73
Current: 45.73
-39.63
45.73
Net-margin (%) 44.06
ENZ's Net-margin (%) is ranked higher than
99% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. ENZ: 44.06 )
Ranked among companies with meaningful Net-margin (%) only.
ENZ' s Net-margin (%) Range Over the Past 10 Years
Min: -38.09  Med: -16.58 Max: 44.06
Current: 44.06
-38.09
44.06
ROE (%) 78.95
ENZ's ROE (%) is ranked higher than
99% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. ENZ: 78.95 )
Ranked among companies with meaningful ROE (%) only.
ENZ' s ROE (%) Range Over the Past 10 Years
Min: -56.99  Med: -16.22 Max: 78.95
Current: 78.95
-56.99
78.95
ROA (%) 54.96
ENZ's ROA (%) is ranked higher than
100% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. ENZ: 54.96 )
Ranked among companies with meaningful ROA (%) only.
ENZ' s ROA (%) Range Over the Past 10 Years
Min: -43.97  Med: -13.85 Max: 54.96
Current: 54.96
-43.97
54.96
ROC (Joel Greenblatt) (%) 398.06
ENZ's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. ENZ: 398.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENZ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -230.98  Med: -98.58 Max: 398.06
Current: 398.06
-230.98
398.06
Revenue Growth (3Y)(%) -2.30
ENZ's Revenue Growth (3Y)(%) is ranked lower than
63% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. ENZ: -2.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ENZ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.9  Med: 3.6 Max: 24.5
Current: -2.3
-9.9
24.5
» ENZ's 10-Y Financials

Financials (Next Earnings Date: 2017-03-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ENZ Guru Trades in Q4 2015

Jim Simons 1,253,100 sh (+12.57%)
» More
Q1 2016

ENZ Guru Trades in Q1 2016

Jim Simons 1,449,900 sh (+15.71%)
» More
Q2 2016

ENZ Guru Trades in Q2 2016

Jim Simons 1,866,981 sh (+28.77%)
» More
Q3 2016

ENZ Guru Trades in Q3 2016

Jim Simons 1,957,368 sh (+4.84%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:OXFD, NAS:SRDX, NAS:ONVO, NAS:LNTH, NAS:RDNT, NAS:TRIB, AMEX:SENS, NYSE:NVTA, NAS:TTOO, NAS:HSKA, NAS:NVDQ, NAS:NRCIA, NAS:CTSO, NAS:PMD, NAS:QTNT, AMEX:VNRX, OTCPK:EPGNF, NAS:BEAT, NAS:TROV, NAS:CEMI » details
Traded in other countries:EZB.Germany,
Enzo Biochem Inc is engaged in research, development, manufacturing and marketing of health care products, platforms and services. The Company's business segments are Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics.

Enzo Biochem Inc was founded in 1976. It is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. The Company develops, manufactures and sells its proprietary technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians. The Company's business segments are Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics. The Enzo Clinical Labs is a clinical reference laboratory provides clinical services to a physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Underpinned by broad technological capabilities, Enzo Life Sciences has developed proprietary products used in the identification of genomic information by laboratories around the world. The Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. It owns or license 314 patents relating to products, methods and procedures resulting from its internal or sponsored research projects. The Company distributes its life science products internationally through a network of distributors. It competes with other life science and biotechnology companies, as well as pharmaceutical, chemical and other companies. The Company is subject to licensing and regulation under federal, state and local laws relating to the handling and disposal of medical specimens, infectious and hazardous waste.

Ratios

vs
industry
vs
history
P/E(ttm) 7.31
ENZ's P/E(ttm) is ranked higher than
95% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. ENZ: 7.31 )
Ranked among companies with meaningful P/E(ttm) only.
ENZ' s P/E(ttm) Range Over the Past 10 Years
Min: 5.25  Med: 11.89 Max: 34.86
Current: 7.31
5.25
34.86
PE(NRI) 7.31
ENZ's PE(NRI) is ranked higher than
95% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. ENZ: 7.31 )
Ranked among companies with meaningful PE(NRI) only.
ENZ' s PE(NRI) Range Over the Past 10 Years
Min: 5.25  Med: 11.89 Max: 34.86
Current: 7.31
5.25
34.86
Price/Owner Earnings (ttm) 6.93
ENZ's Price/Owner Earnings (ttm) is ranked higher than
90% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.10 vs. ENZ: 6.93 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ENZ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.94  Med: 11.86 Max: 31.48
Current: 6.93
4.94
31.48
P/B 3.70
ENZ's P/B is ranked lower than
52% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.41 vs. ENZ: 3.70 )
Ranked among companies with meaningful P/B only.
ENZ' s P/B Range Over the Past 10 Years
Min: 0.85  Med: 2.92 Max: 7.17
Current: 3.7
0.85
7.17
P/S 3.21
ENZ's P/S is ranked higher than
51% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. ENZ: 3.21 )
Ranked among companies with meaningful P/S only.
ENZ' s P/S Range Over the Past 10 Years
Min: 0.56  Med: 2.03 Max: 13.48
Current: 3.21
0.56
13.48
PFCF 6.43
ENZ's PFCF is ranked higher than
92% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.06 vs. ENZ: 6.43 )
Ranked among companies with meaningful PFCF only.
ENZ' s PFCF Range Over the Past 10 Years
Min: 4.59  Med: 10.04 Max: 22.18
Current: 6.43
4.59
22.18
POCF 6.25
ENZ's POCF is ranked higher than
88% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.55 vs. ENZ: 6.25 )
Ranked among companies with meaningful POCF only.
ENZ' s POCF Range Over the Past 10 Years
Min: 4.45  Med: 9.11 Max: 18.48
Current: 6.25
4.45
18.48
EV-to-EBIT 5.67
ENZ's EV-to-EBIT is ranked higher than
93% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.61 vs. ENZ: 5.67 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -64  Med: -7.8 Max: 32.8
Current: 5.67
-64
32.8
EV-to-EBITDA 5.26
ENZ's EV-to-EBITDA is ranked higher than
93% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.28 vs. ENZ: 5.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -42.1  Med: -9.75 Max: 75.2
Current: 5.26
-42.1
75.2
Current Ratio 4.44
ENZ's Current Ratio is ranked higher than
74% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ENZ: 4.44 )
Ranked among companies with meaningful Current Ratio only.
ENZ' s Current Ratio Range Over the Past 10 Years
Min: 1.36  Med: 11.12 Max: 33.47
Current: 4.44
1.36
33.47
Quick Ratio 4.10
ENZ's Quick Ratio is ranked higher than
75% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. ENZ: 4.10 )
Ranked among companies with meaningful Quick Ratio only.
ENZ' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 10.7 Max: 32.01
Current: 4.1
1
32.01
Days Inventory 46.36
ENZ's Days Inventory is ranked higher than
64% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.17 vs. ENZ: 46.36 )
Ranked among companies with meaningful Days Inventory only.
ENZ' s Days Inventory Range Over the Past 10 Years
Min: 45.85  Med: 60.2 Max: 75.03
Current: 46.36
45.85
75.03
Days Sales Outstanding 51.82
ENZ's Days Sales Outstanding is ranked higher than
62% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. ENZ: 51.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.29  Med: 50.46 Max: 99.02
Current: 51.82
45.29
99.02
Days Payable 62.91
ENZ's Days Payable is ranked higher than
52% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.52 vs. ENZ: 62.91 )
Ranked among companies with meaningful Days Payable only.
ENZ' s Days Payable Range Over the Past 10 Years
Min: 29.18  Med: 55.95 Max: 64.59
Current: 62.91
29.18
64.59

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
ENZ's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. ENZ: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENZ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.1  Med: -1.3 Max: -0.4
Current: -4.5
-6.1
-0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.20
ENZ's Price/Net Cash is ranked higher than
68% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.60 vs. ENZ: 7.20 )
Ranked among companies with meaningful Price/Net Cash only.
ENZ' s Price/Net Cash Range Over the Past 10 Years
Min: 5.33  Med: 8.72 Max: 42.67
Current: 7.2
5.33
42.67
Price/Net Current Asset Value 4.74
ENZ's Price/Net Current Asset Value is ranked higher than
76% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. ENZ: 4.74 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ENZ' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.88  Med: 5.63 Max: 18.91
Current: 4.74
2.88
18.91
Price/Tangible Book 4.20
ENZ's Price/Tangible Book is ranked higher than
58% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. ENZ: 4.20 )
Ranked among companies with meaningful Price/Tangible Book only.
ENZ' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.97  Med: 4.84 Max: 17.27
Current: 4.2
1.97
17.27
Price/Projected FCF 3.41
ENZ's Price/Projected FCF is ranked lower than
65% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. ENZ: 3.41 )
Ranked among companies with meaningful Price/Projected FCF only.
ENZ' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.43  Med: 3.98 Max: 11.1
Current: 3.41
2.43
11.1
Price/Median PS Value 1.57
ENZ's Price/Median PS Value is ranked lower than
81% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. ENZ: 1.57 )
Ranked among companies with meaningful Price/Median PS Value only.
ENZ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.28  Med: 3.5 Max: 13.62
Current: 1.57
0.28
13.62
Price/Peter Lynch Fair Value 2.35
ENZ's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 23 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.88 vs. ENZ: 2.35 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ENZ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0  Med: 4.5 Max: 6.81
Current: 2.35
0
6.81
Price/Graham Number 1.17
ENZ's Price/Graham Number is ranked higher than
85% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. ENZ: 1.17 )
Ranked among companies with meaningful Price/Graham Number only.
ENZ' s Price/Graham Number Range Over the Past 10 Years
Min: 1.1  Med: 6.09 Max: 13.01
Current: 1.17
1.1
13.01
Earnings Yield (Greenblatt) (%) 17.65
ENZ's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. ENZ: 17.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENZ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.1  Med: 9.7 Max: 27.1
Current: 17.65
3.1
27.1
Forward Rate of Return (Yacktman) (%) 33.77
ENZ's Forward Rate of Return (Yacktman) (%) is ranked higher than
90% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.71 vs. ENZ: 33.77 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ENZ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -31.2  Med: -4.1 Max: 33.77
Current: 33.77
-31.2
33.77

More Statistics

Revenue (TTM) (Mil) $102.8
EPS (TTM) $ 0.97
Beta1.54
Short Percentage of Float2.15%
52-Week Range $4.00 - 7.51
Shares Outstanding (Mil)46.28

Analyst Estimate

Jul17
Revenue (Mil $)
EPS ($) -0.15
EPS w/o NRI ($) -0.15
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ENZ

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, DDMG, ZHNE, ENZ, SIRO Nov 28 2011 
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Mar 14 2011 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Jun 09 2010 
Enzo Biochem Inc. Reports Operating Results (10-Q) Dec 10 2009 
Weekly Top Insider Buys: Bank of America Corp., Safeway Inc., Umpqua Holdings Corp., National Penn B Oct 24 2009 
Weekly Top Insider Buys: KB Home, National Penn Bancshares Inc., Moduslink Global Solutions Inc., En Oct 20 2009 
Enzo Biochem Inc. Reports Operating Results (10-Q) Sep 04 2009 
Enzo Biochem Inc. (ENZ) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
Enzo Biochem, Inc. (ENZ): Are Hedge Funds Right About This Stock? Dec 09 2016
ENZO BIOCHEM INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Dec 08 2016
Enzo Biochem reports 1Q loss Dec 08 2016
Enzo Biochem reports 1Q loss Dec 08 2016
Enzo Biochem Reports Improved First Quarter Results Dec 08 2016
ETFs with exposure to Enzo Biochem, Inc. : December 8, 2016 Dec 08 2016
Q1 2017 Enzo Biochem Inc Earnings Release - After Market Close Dec 08 2016
5 Reasonable Breakout Stocks for Exceptional Returns Dec 08 2016
Is Daktronics, Inc. (DAKT) A Good Stock To Buy? Dec 04 2016
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2017 Results Friday, December 9, 2016... Dec 01 2016
ETFs with exposure to Enzo Biochem, Inc. : November 23, 2016 Nov 23 2016
Trump meets with The Times Nov 22 2016
Sullivan's spectacular stats from Dow's historic run Nov 22 2016
Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: 2016 By the Numbers : November 22, 2016 Nov 22 2016
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte Nov 11 2016
Zacks.com featured highlights: include Cambrex, Enzo Biochem, Alliqua BioMedical, CubeSmart and... Nov 10 2016
ETF’s with exposure to Enzo Biochem, Inc. : October 31, 2016 Oct 31 2016
ETF’s with exposure to Enzo Biochem, Inc. : October 21, 2016 Oct 21 2016
Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q4, 2016 By the Numbers : October 20, 2016 Oct 20 2016
ENZO BIOCHEM INC Financials Oct 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)